Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Quote. Delayed NASDAQ OMX COPENHAGEN - 10/23 10:59:47 am
445.25 DKK   +0.26%
10/16NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/14NOVO NORDISK : Buy rating from JP Morgan
MD
10/12NOVO NORDISK : Credit Suisse gives a Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : Karolinska Institutet, St. Erik Eye Hospital and Novo Nordisk collaborate to find a cure for age-related macular degeneration

share with twitter share with LinkedIn share with facebook
08/25/2020 | 06:56am EDT

Karolinska Institutet and St. Erik Eye Hospital have entered into a collaboration with Novo Nordisk A/S to develop a new treatment for age-related macular degeneration.

Novo Nordisk A/S will provide support and SEK 48 million in funding to enable a phase 1 clinical trial where new retinal cells generated from embryonic stem cells will be transplanted into patients. The aim is to develop a completely new cell therapy for this common but currently incurable eye disease.

Karolinska Institutet and St. Erik Eye Hospital have conducted joint research on cell therapies since 2013. The collaboration with the Danish pharmaceutical company Novo Nordisk A/S is based on this research and will focus on developing new retinal cells from embryonic stem cells with the aim of testing these in a small clinical trial. The ultimate goal is to find a curative treatment for the severe form of age-related macular degeneration that affects some 1,500 patients in Sweden every year. In age-related macular degeneration, the cells in the retinal macula stop working normally, causing gradual loss of sight in the central visual field.

The work has progressed all the way from basic research on how embryos and stem cells work, via establishing a new method of production of specific eye cells, to be on track to test these in a first clinical trial.

A breakthrough

'This will be the first transplantation of retinal cells differentiated from embryonic stem cells performed in Sweden, and it is a breakthrough that's been made possible thanks to years of hard work by a great many people,' says Fredrik Lanner, researcher at the Department of Clinical Science, Intervention and Technology and the Ming Wai Lau Centre for Reparative Medicine at Karolinska Institutet. 'With the support of Novo Nordisk, in terms of competence as well as financially, we can now get close to the goal of a new cell therapy.'

'We have an effective recipe for producing the cells using a robust yet simple method of cultivation,' continues Dr Lanner. 'It makes the method easier to scale up for larger volumes and more viable for use in a future cell-therapy product.'

In this first-in-human trial, each patient will receive the new cells via subretinal injection. The researchers will, in the first instance, establish the safety of the method, while also studying the cells' ability to adhere and slow down the disease process.

Complex technology

'This is in many ways a unique project and it is very exciting that we now have the opportunity to take it further to clinical trials where we hope to be able to save the sight of a large group of patients,' says Anders Kvanta, professor at the Department of Clinical Neuroscience, Karolinska Institutet and consultant at St. Erik Eye Hospital who is responsible for the clinical study. 'But we respect the fact that it is a complex technology and a challenging disease and that it may take many years for this to be developed into a curative treatment.'

'We are excited to enter into this collaboration with Professor Anders Kvanta and Dr Fredrik Lanner,' says Jacob Sten Petersen, Corporate Vice President and Head of Stem Cell R&D at Novo Nordisk. 'They are both world-leading experts within stem cell research and treatment of eye diseases. Through this partnership we have a unique opportunity to combine the Novo Nordisk strong stem cell R&D capabilities with cutting edge science and clinical research at Karolinska Institutet and St. Erik Eye Hospital, to develop a novel cell therapy for people living with dry age-related macular degeneration.'

(C) 2020 Electronic News Publishing, source ENP Newswire


share with twitter share with LinkedIn share with facebook
All news about NOVO NORDISK A/S
10/16NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/14NOVO NORDISK : Buy rating from JP Morgan
MD
10/12NOVO NORDISK : Credit Suisse gives a Buy rating
MD
10/12NOVO NORDISK A/S : Bavarian Nordic Announces Appointment of Anu Helena Kerns as ..
AQ
10/12NOVO NORDISK A/S : Conference call regarding updated 2020 outlook 9 October 2020
PU
10/12NOVO NORDISK A/S : Alexander Mann Solutions partners with Novo Nordisk to suppor..
AQ
10/12NOVO NORDISK A/S : – Share repurchase programme
AQ
10/09EUROPE : European stocks rack up second week of gains, Pandora leaps
RE
10/09NOVO NORDISK : Credit Suisse gives a Buy rating
MD
10/09GLOBAL MARKETS LIVE : Acquisitions, acquisitions, acquisitions
More news
Financials
Sales 2020 128 B 20 361 M 20 361 M
Net income 2020 42 192 M 6 727 M 6 727 M
Net cash 2020 10 613 M 1 692 M 1 692 M
P/E ratio 2020 24,7x
Yield 2020 2,02%
Capitalization 1 035 B 165 B 165 B
EV / Sales 2020 8,02x
EV / Sales 2021 7,50x
Nbr of Employees 43 526
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 447,63 DKK
Last Close Price 445,25 DKK
Spread / Highest target 22,4%
Spread / Average Target 0,53%
Spread / Lowest Target -31,5%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S15.16%164 690
JOHNSON & JOHNSON-0.43%382 391
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999